Issuer/Instrument | Industry/ Rating |
% to Net Assets |
---|---|---|
Equity & Equity Related |
||
Reliance Industries Ltd. | Petroleum Products | 12.80 |
Infosys Ltd. | Software | 9.88 |
HDFC Bank Ltd. | Banks | 9.82 |
ICICI Bank Ltd. | Banks | 8.10 |
HDFC Ltd. | Finance | 6.73 |
Tata Consultancy Services Ltd. | Software | 5.79 |
Kotak Mahindra Bank Ltd. | Banks | 3.79 |
Larsen And Toubro Ltd. | Construction Project | 3.45 |
Axis Bank Ltd. | Banks | 3.19 |
Hindustan Unilever Ltd. | Consumer Non Durables | 3.05 |
ITC Ltd. | Consumer Non Durables | 2.97 |
Bajaj Finance Ltd. | Finance | 2.93 |
State Bank Of India | Banks | 2.92 |
Bharti Airtel Ltd | Telecom - Services | 2.61 |
Asian Paints Ltd. | Consumer Non Durables | 2.25 |
HCL Technologies Ltd. | Software | 1.92 |
Maruti Suzuki India Limited | Auto | 1.74 |
Titan Company Ltd. | Consumer Durables | 1.67 |
Bajaj Finserv Ltd. | Insurance | 1.52 |
Tata Steel Ltd. | Ferrous Metals | 1.50 |
Sun Pharmaceuticals Industries Ltd. | Pharmaceuticals | 1.43 |
Tech Mahindra Ltd. | Software | 1.38 |
Wipro Ltd. | Software | 1.29 |
Mahindra & Mahindra Ltd. | Auto | 1.19 |
Ultratech Cement Ltd. | Cement & Cement Products | 1.19 |
Power Grid Corporation Of India Ltd. | Power | 1.12 |
National Thermal Power Corporation Limited | Power | 1.00 |
Nestle India Ltd. | Consumer Non Durables | 0.99 |
IndusInd Bank Ltd. | Banks | 0.87 |
Dr Reddys Laboratories Ltd. | Pharmaceuticals | 0.78 |
Equity & Equity Related - Total | 99.87 | |
Net Current Assets/(Liabilities) | 0.13 | |
Grand Total | 100.00 |
Regular Plan
Fund Manager | Mr. Devender Singhal & Mr. Satish Dondapati* |
Benchmark | S&P BSE SENSEX TRI |
Allotment date | June 6, 2008 |
AAUM | Rs20.67 crs |
AUM | Rs20.17 crs |
Folio count | 1,340 |
Portfolio Turnover | 16.83% |
Tracking Error: | 0.10% |
Through Exchange: 1 Unit ,
Through AMC: 10000 Units,
Ideal Investment Horizon: 5 years and
above
Entry Load: Nil. (applicable for all plans)
Exit Load:
Nil (applicable for all plans)
Regular: 0.28%
Fund
Benchmark
* Investors should consult their financial advisers if in doubt about whether the product is suitable for them.